FIELD: medicine, oncology, medicinal microbiology. SUBSTANCE: bacterial mass of culture BCG-1 is filtered and diluted with stabilizing agent for two stages. After the first dilution up to concentration 50-60 mg of BCG in 1 ml the obtained suspension is centrifuged at separation factor 250 for 5 min and then the second dilution is carried out up to concentration 25 or 30 mg of BCG in 1 ml. Vaccine is poured into ampoules in the dose 1 ml and lyophilized. Invention provides to obtain standard curative vaccine with concentration 25 or 30 mg of BCG in 1 ml. EFFECT: enhanced indices of viability, homogeneity, dispersity and solubility. 2 tbl, 3 ex _
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREPARING VACCINE BCG-M FOR SPARING PRIMARY IMMUNIZATION | 2000 |
|
RU2170588C1 |
| METHOD OF STREPTOCOCCUS HYALURONIDASE PREPARING | 2000 |
|
RU2174557C1 |
| METHOD OF PREPARING PURIFIED LIQUID STAPHYLOCOCCUS ANATOXIN FOR SPECIFIC IMMUNOTHERAPY OF PATIENTS WITH STAPHYLOCOCCUS INFECTION | 2000 |
|
RU2169580C1 |
| RECTAL SUPPOSITORIUM | 1998 |
|
RU2139043C1 |
| BCG-BASED IMMUNOBIOLOGICAL MEDICATION FOR URINARY BLADDER CANCER THERAPY AND METHOD FOR THEREOF APPLICATION | 2014 |
|
RU2571822C1 |
| METHOD OF COMPLEX TREATMENT AND PREVENTION OF RECURRENCES OF MUSCULAR-NON-INVASIVE FORMS OF URINARY BLADDER CANCER | 2013 |
|
RU2560314C2 |
| IMMUNOBIOLOGICAL AGENT FOR TREATING URINARY BLADDER CANCER AND METHOD OF APPLICATION THEREOF | 2013 |
|
RU2555327C2 |
| METHOD OF INHIBITING PD-1/PD-L1 SIGNALING PATHWAY IN BLADDER CANCER CELLS | 2023 |
|
RU2812805C1 |
| METHOD FOR DETECTING CYTOPROLIFERATIVE FACTOR IN AGING MAMMALIAN AND HUMAN BODIES IN THEIR LIFETIME | 2001 |
|
RU2204135C2 |
| PHARMACEUTICAL COMPOSITION EXHIBITING CYTOTOXIC EFFECT ON HUMAN BLADDER CANCER CELLS | 2018 |
|
RU2693378C1 |
